Biotec Pharmacon presents its report for the first quarter 2016 on Tuesday, 19th April. The presentation will be given by CEO Svein Lien and Vice President Marketing Stuart Devine.
The presentation starts at 08:30 am and will be in English.
Venue: Hotell Continental, Stortingsgata 24, Oslo.
The presentation can also be followed as a live webcast from Hegnar TV on www.biotec.no, and it will be possible to post questions through the webcast console at the end of the presentation. The interim report for … continue reading »
(Tromsø 01. April 2016) Biotec Pharmacon ASA (“Biotec”,OSE: BIOTEC) is pleased to announce that ArcticZymes, a subsidiary of Biotec Pharmacon has received EUR 460.000 over the next four years in a project funded by the European Framework Programme for Research and Innovation, Horizon 2020.
“We are excited to participate in the new granted “Virus-X” EU Consortium. It will allow ArcticZymes to expand its access to novel molecular enzymes via the bioprospecting of a wide diversity of viral genomes.”, says Jethro Holter, Managing … continue reading »
(Tromsø, 31 March 2016) Biotec Pharmacon ASA (”Biotec”, OSE: BIOTEC) announced today the launch of a new website for Woulgan®, along with a dedicated product Facebook page.
– Biotec is pleased to unveil a new website focused solely on the Woulgan product. The site, along with a brand new Facebook page, will enable wound care specialists, general clinicians, as well as patients and patient interest groups to access reference materials, product information sheets and news, says Svein Lien, CEO of … continue reading »
Biotec BetaGlucans AS has received ISO certification for Development, manufacturing, sales and distribution of Beta-Glucans for wound treatment, animal Health, Food supplements and cosmetics
(Tromsø 11. March 2016) Biotec Pharmacon ASA’s (OSE:BIOTEC) subsidiary Biotec BetaGlucans AS has today entered into a supplier agreement with a new feed company for deliveries of its beta-glucan product M-Glucan for use in animal health.
Deliveries under the agreement will commence from May 1st 2016 and run for 24 months. Expected revenues for the indicated period is around NOK 20 million depending on sales.
“We are very pleased to sign up new customers for our well documented animal health product as … continue reading »
Biotec Pharmacon ASA (OSE: BIOTEC) has received a Notice of Allowance for its Woulgan gel in the US.
The allowed patent application has the application number US 13/989,594, title of invention: Glucan Gels. The claims cover the gel glucan product comprising SBG, a method of producing the gel glucan product and the product obtainable by this method as well as a medical composition comprising the gel glucan.
“We are very pleased with this patent as it will open up for opportunities in the … continue reading »
ArcticZymes, together with BioTech North, was featured in the latest edition of “Oslo Chamber of Commerce’s” Mercur magazine. The article describes some of ArcticZymes key features and possibilities in the cold arctic ocean outside of Norhtern Norway
The presentation following the Capital Markets Day is available for download in pdf format.
(Tromsø, 3 February 2016) Biotec Pharmacon ASA (”Biotec”), OSE: BIOTEC) will host a Capital Markets Day (CMD) Thursday 11 February 2016, following the Q4 presentation.
Time: 08:30 – 11:00
Location: Hotel Continental, Stortingsgaten 24/26, 0117 Oslo
Breakfast will be served prior to the presentations. For practical reasons, investors, analysts and journalists are encouraged to register via email to firstname.lastname@example.org by 8 February 2016.
Capital Markets Day agenda
0830 – 0900 Q4 Presentation, Svein Lien, CEO
0905 – 0905 CMD Introduction, Svein Lien, CEO
0905 – … continue reading »